<DOC>
	<DOC>NCT00774553</DOC>
	<brief_summary>The purpose of this study is to assess safety and tolerablility of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of metformin.</brief_summary>
	<brief_title>To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male or female (with non childbearing potential) Diagnosed diabetes Mellitus patients treated with metformin alone or one other antidiabetic drugs. Stable blood sugar control indicated by no changed treatment within 3 months prior to study start.t HbA1c &lt;11 % at screening (HbA1c value according to international DCCT standard) Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP History of ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>